Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma.
Pires da Silva I, Zakria D, Ahmed T, Trojanello C, Dimitriou F, Allayous C, Gerard C, Zimmer L, Lo S, Michielin O, Lebbe C, Mangana J, Ascierto PA, Johnson DB, Carlino M, Menzies A, Long G. Pires da Silva I, et al. Among authors: allayous c. J Immunother Cancer. 2022 Jul;10(7):e004610. doi: 10.1136/jitc-2022-004610. J Immunother Cancer. 2022. PMID: 35798536 Free PMC article.
Reply to 'Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance' by Funck-Brentano et al.
Goldwirt L, Chami I, Feugeas JP, Pages C, Brunet-Possenti F, Allayous C, Baroudjian B, Madelaine I, Sauvageon H, Mourah S, Lebbé C. Goldwirt L, et al. Among authors: allayous c. Ann Oncol. 2016 Feb;27(2):363-4. doi: 10.1093/annonc/mdv538. Epub 2015 Nov 16. Ann Oncol. 2016. PMID: 26578723 Free article. No abstract available.
Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.
Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C. Tétu P, et al. Among authors: allayous c. Eur J Cancer. 2019 May;112:38-46. doi: 10.1016/j.ejca.2019.02.009. Epub 2019 Mar 22. Eur J Cancer. 2019. PMID: 30909072
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.
Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C; for MelBase. Vallet A, et al. Among authors: allayous c. JAMA Dermatol. 2019 Jun 1;155(6):673-678. doi: 10.1001/jamadermatol.2019.0425. JAMA Dermatol. 2019. PMID: 31042256 Free PMC article.
Severe gastrointestinal toxicity of MEK inhibitors.
Mourad N, Lourenço N, Delyon J, Eftekhari P, Bertheau P, Allayous C, Ballon A, Pagès C, Allez M, Lebbé C, Baroudjian B; PATIO group. Mourad N, et al. Among authors: allayous c. Melanoma Res. 2019 Oct;29(5):556-559. doi: 10.1097/CMR.0000000000000618. Melanoma Res. 2019. PMID: 31095035
Quality-of-life assessment in French patients with metastatic melanoma in real life.
Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Kandel M, et al. Among authors: allayous c. Cancer. 2020 Feb 1;126(3):611-618. doi: 10.1002/cncr.32554. Epub 2019 Oct 22. Cancer. 2020. PMID: 31639198 Free article.
40 results